Keryx Licenses Japanese Rights For Zerenex To Japan Tobacco In $100 Million Deal
This article was originally published in PharmAsia News
Executive Summary
Keryx Biopharmaceuticals got a major boost Sept. 26 in its effort to bring the Phase II hyperphosphatemia candidate Zerenex to the worldwide market by signing a licensing agreement potentially worth up to $100 million with Japan Tobacco and its subsidiary, Torii Pharmaceutical
You may also be interested in...
Genzyme Gets Mixed Results On Renvela Powder Formulation
An NDA for the tablet form of the follow-on chronic kidney disease therapy is pending at FDA.
Amgen Gains Phase II Phosphate Binder With Acquisition of Ilypsa
Ilypsa’s lead candidate, ILY1001, for treatment of hyperphosphatemia in chronic kidney disease, complements Amgen’s anemia agents.
Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.